ATRA

Atara Biotherapeutics Inc

Add to Watchlist

Advanced Chart

11.810

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.810

Open

11.810

VWAP

Vol

2.27K

Mkt Cap

79.05M

Low

11.810

Amount

EV/EBITDA(TTM)

16.89

Total Shares

4.90M

106.98M

EV/OCF(TTM)

P/S(TTM)

0.50

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

4.23M

-85.25%

-0.320

-89.68%

16.68M

-58.51%

-0.320

-89.08%

10.58M

-67.71%

-0.320

-73.11%

Estimates Revision

The market is revising Upward the revenue expectations for Atara Biotherapeutics, Inc. (ATRA) for FY2025, with the revenue forecasts being adjusted by 27.94% over the past three months. During the same period, the stock price has changed by 57.26%.

Revenue Estimates for FY2025

Revise Upward

+27.94%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+57.26%

In Past 3 Month

1 Analyst Rating

43.95% Upside

Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

43.95% Upside

Current: 11.810

Low

17.00

Averages

17.00

High

17.00

43.95% Upside

Current: 11.810

Low

17.00

Averages

17.00

High

17.00

Canaccord Genuity

John Newman

Strong Buy

Maintains

$17

2025-03-11

Reason

Canaccord Genuity

John Newman

Price Target

$17

2025-03-11

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Hold

Reiterates

n/a

2025-01-28

Reason

HC Wainwright & Co.

Robert Burns

Price Target

n/a

2025-01-28

Reiterates

Hold

Reason

HC Wainwright & Co.

Robert Burns

Hold

Reiterates

n/a

2025-01-22

Reason

HC Wainwright & Co.

Robert Burns

Price Target

n/a

2025-01-22

Reiterates

Hold

Reason

Canaccord Genuity

John Newman

Strong Buy

Maintains

$21 → $17

2025-01-17

Reason

Canaccord Genuity

John Newman

Price Target

$21 → $17

2025-01-17

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Atara Biotherapeutics to $17 from $21 and keeps a Buy rating on the shares. The firm noted Atara received a Complete Response Letter (CRL) for Ebvallo on inspection findings from a third-party manufacturer, which we think can be resolved, with a 6-month review on resubmission. The target was reduced due to delayed Ebvallo approval and the potential to halt CAR-T development 1Q25.

Rodman & Renshaw

Tony Butler

Strong Buy

Initiates

$25

2024-12-20

Reason

Rodman & Renshaw

Tony Butler

Price Target

$25

2024-12-20

Initiates

Strong Buy

Reason

Rodman & Renshaw analyst Tony Buter initiated coverage of Atara Biotherapeutics with a Buy rating and $25 price target. Atara is developing T-cell immunotherapies with a focus on the development of therapies for patients with cancer and autoimmune diseases, the analyst tells investors in a research note. The firm believes Atara is unique for a number of reasons among allogeneic cell therapy developers given its use of intact T-cell receptors, the incorporation of the 1XX chimeric antigen receptors, and the use of T-cells with memory stem cell phenotype.

Canaccord Genuity

John Newman

Strong Buy

Maintains

$13 → $21

2024-11-13

Reason

Canaccord Genuity

John Newman

Price Target

$13 → $21

2024-11-13

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Atara Biotherapeutics Inc (ATRA.O) is 7.00, compared to its 5-year average forward P/E of -1.96. For a more detailed relative valuation and DCF analysis to assess Atara Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.96

Current PE

7.00

Overvalued PE

0.55

Undervalued PE

-4.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.21

Current EV/EBITDA

16.43

Overvalued EV/EBITDA

1.95

Undervalued EV/EBITDA

-4.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.24

Current PS

2.26

Overvalued PS

43.99

Undervalued PS

-9.52

Financials

Annual

Quarterly

FY2025Q1

YoY :

+258.77%

98.15M

Total Revenue

FY2025Q1

YoY :

-298.95%

52.72M

Operating Profit

FY2025Q1

YoY :

-219.71%

38.01M

Net Income after Tax

FY2025Q1

YoY :

-161.95%

3.50

EPS - Diluted

FY2025Q1

YoY :

-5.38%

-28.14M

Free Cash Flow

FY2025Q1

YoY :

-14.62%

79.18

Gross Profit Margin - %

FY2025Q1

YoY :

-93.68%

-33.73

FCF Margin - %

FY2025Q1

YoY :

-133.37%

38.73

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

37.2K

USD

3-6

Months

39.2K

USD

6-9

Months

45.1K

USD

0-12

Months

53.4K

USD

Bought

0-3

186.4K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 192.53% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

30.9K

Volume

6-9

Months

10.6K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

41.0K

Volume

Months

6-9

39.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

37.2K

USD

3-6

Months

39.2K

USD

6-9

Months

45.1K

USD

0-12

Months

53.4K

USD

Bought

0-3

186.4K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ATRA News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

09:01:34

Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA

2025-07-24

08:03:16

Atara Biotherapeutics announces FDA acceptance of BLA for tabelecleucel

2025-07-15 (ET)

2025-07-15

08:09:24

Atara Biotherapeutics completes transfer of INDA for tabelecleucel to partner

News

9.0

07-24NASDAQ.COM

Atara To Face FDA Again In Jan.2026 - Will The Second Time Be The Charm For Tab-cel?

9.0

07-24SeekingAlpha

Atara gets FDA priority review for Tabelecleucel application

9.0

07-24PRnewswire

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)